• Mark Day, VP Research & Emerging Sciences, Otsuka Pharmaceuticals
Mark Day Ph.D. is the Vice President and head of the Otsuka U.S. McQuade Centre for R&D & Early Stage Life Science Investment (MSRD) and has more than 20 years of experience working in the industry.
Dr. Day is widely recognized for his expertise and success in the recognition, evaluation and development of pipeline acquisition and collaboration targets across several therapeutic areas, including complement, oncology and neurological diseases and disorders. He has authored more than 60 peer-reviewed manuscripts on translational medicine, impulsivity, stroke, cognitive dysfunction in neurological and psychiatric illness such as Alzheimer’s diseases and ADHD, including first authorships in Nature, Science, Nature Neuroscience, Neuroimaging, Proceedings of the Royal Society. Most recently, Dr. Day was the former director, chief executive officer, president and chief scientific officer at Bioasis Technologies Inc., a pre-clinical, research-stage biopharmaceutical company developing its proprietary platform technology for the delivery of therapeutics across the blood-brain barrier and the treatment of central nervous system disorders, including brain cancers and neurodegenerative diseases.
Dr. Day currently serves as an adjunct associate professor of translational neuroscience at Yale University and independent non-executive director at NanoViricides (NYSE:NNVC). He has also previously served on the board of directors and scientific advisory boards of other public and private companies.
He has developed business plans for Alexion Pharmaceuticals, AbbVie, Wyeth, Glaxo Smith Kline (GSK) and Bristol-Myers Squibb (BMS) in multiple functional areas ranging from the development of external research discovery engines and global scouting strategies to the creation of internal venture/investment funds. He has established and managed more than 20 collaborations, mergers and acquisitions and licensing deals in R&D and business development.
Dr. Day previously served as the head of translational medicine neuroscience at Wyeth and was the co-chair of the early development team. At Abbott, he was responsible for translational imaging and biomarkers across the R&D portfolios. At BMS, Dr. Day was instrumental in the acquisition of iPierian and he has developed strategies that can shorten evaluation periods by several months, leading to early decisions regarding the advancement or early termination of the evaluative processes. Dr. Day was also previously the head, CNS virtual discovery, at Purdue Pharma. Prior to joining Purdue Pharma, he served as executive director, head of external research and scouting, at Alexion Pharmaceuticals, Inc.
Dr. Day earned his bachelor of science degree in biological psychology and his doctor of philosophy degree in neuroscience from Cardiff University. He completed his post doctorate studies in systems level neuroscience at The University of Edinburgh under Professor Richard G. Morris, FRS., FRSE.